WAYNE and UTRECHT – Oct. 22, 2024 — NanoCell Therapeutics, Inc. (“NanoCell”), a company developing in-vivo cell engineering solutions based on its proprietary non-viral, DNA-based gene therapy platform, today announced that the team will present at several upcoming investor and scientific conferences.
Initial data from the company’s ongoing preclinical studies on targeted lipid nanoparticle (tLNP) technology for in vivo CAR-T cell generation will be presented at the ESGCT by Dr. Jacek Lubelski, NanoCell’s Chief Technology Officer. The presentation will highlight preclinical results demonstrating the ability of the company’s novel tLNP technology to generate persistent CAR-T cells in vivo, showing tumor control and extended survival in a human PBMC engrafted mouse model of B-cell leukemia.
At the SITC 39th Annual Meeting and the SITC Immune Engineering Workshop in Houston, Texas, Dr. Lubelski will present new data from the company’s non-viral vector platform research program.
NanoCell will participate in two upcoming investor conferences. Dr. Maurits Geerlings, CEO, will join a panel discussion and host investor meetings at the Longwood Healthcare Leaders Boston CEO Forum (October 28-29, 2024), followed by one-on-one investor meetings at BioEurope in Stockholm (November 4-6, 2024).
Presentation Details:
European Society of Gene & Cell Therapy (ESGCT):
Oral Presentation: “tLNPs can effectively deliver DNA to T-cells and generate long-acting CAR-T cells in vivo”
Number: OR050
Session: Parallel Session 6c: Non Viral Vectors / Nanotechnology I
Location: Meeting Room 2
Timing: Wednesday, October 23rd, 2024,
Timing: 17:30-19:30
Presentation Details:
Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting:
Poster Presentation
Title: “Efficient generation of long-lasting CAR-T cells in vivo using novel non-viral vector”
Abstract Number: 284
Timing: November 8-10, 2024
Location: Houston, TX
Additional Poster Abstract Presentation:
SITC Immune Engineering Workshop:
Titel: “Efficient generation of long-lasting CAR-T cells in vivo using novel non-viral vector”
Timing: November 7, 2024
Location: Houston, TX
Investor Conferences
Event Details:
Longwood Healthcare Leaders Boston CEO Forum
Investor 1:1 Meetings and Panel
Title: Innovation in Cell Therapy
Timing: October 28-29, 2024
Venue: Mandarin Oriental Boston, 776 Boylston Street, Boston, MA, USA
Event Details:
BioEurope
Investor 1:1 Meetings
Company Overview
Timing: November 4–6, 2024
Venue: Stockholmsmässan, Mässvägen 1, 125 30 Älvsjö, Stockholm, Sweden
To learn more about our work and stay updated about our latest developments, please visit our website at http://www.nanocelltx.com.
About NanoCell Therapeutics, Inc.
NanoCell Therapeutics is a privately held, transatlantic biotechnology company with locations in Wayne, Pennsylvania, and Utrecht, the Netherlands. We are dedicated to pioneering transformative in-vivo cell engineering through our non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases. NanoCell’s advanced technology platform aims to evolve and enhance traditional adoptive cell therapy methods into advanced in-vivo treatments. Our objective is to streamline the overall treatment process, bolstering patient access, potential clinical benefits, and cost-effective manufacturing. For more information, visit: http://www.nanocelltx.com.
NanoCell Therapeutics Inc. | Investor Relations
T: +31 (0) 70 3643095 | E: contact@nanocelltx.com